1992
DOI: 10.1111/j.1476-5381.1992.tb14480.x
|View full text |Cite
|
Sign up to set email alerts
|

H3 receptor antagonist, thioperamide, inhibits adrenal steroidogenesis and histamine binding to adrenocortical microsomes and binds to cytochrome P450

Abstract: 1 Thioperamide (TP), an imidazole and a highly potent, specific antagonist of the histamine H3 receptor, inhibited the secretion of cortisol from bovine isolated adrenocortical cells (IC50 0.20 gM) and, in the rat (5 mg kg-1) prevented both basal and stress-induced secretion of corticosterone.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

3
23
0
1

Year Published

1994
1994
2010
2010

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 50 publications
(27 citation statements)
references
References 22 publications
3
23
0
1
Order By: Relevance
“…Although H 3 R agonists contain the imidazole ring, which inhibits P450 isozymes through coordination with their heme moiety, they lack the lipophilic side chain present in antagonists. Consistent with their resulting weak potency at liver microsomes (Brandes et al, 1998) and adrenal P450 enzymes (LaBella et al, 1992;Yang et al, 2002), HA and H 3 R agonists failed to affect the non-H 3 R binding at concentrations up to 0.1 mM. As already reported (Ligneau et al, 1994), the agonist imetit was allowed to discriminate the specific (H 3 R) from the nonspecific (non-H 3 R) binding, although the latter was much higher.…”
Section: Discussionsupporting
confidence: 54%
See 1 more Smart Citation
“…Although H 3 R agonists contain the imidazole ring, which inhibits P450 isozymes through coordination with their heme moiety, they lack the lipophilic side chain present in antagonists. Consistent with their resulting weak potency at liver microsomes (Brandes et al, 1998) and adrenal P450 enzymes (LaBella et al, 1992;Yang et al, 2002), HA and H 3 R agonists failed to affect the non-H 3 R binding at concentrations up to 0.1 mM. As already reported (Ligneau et al, 1994), the agonist imetit was allowed to discriminate the specific (H 3 R) from the nonspecific (non-H 3 R) binding, although the latter was much higher.…”
Section: Discussionsupporting
confidence: 54%
“…First, the non-H 3 R binding was fully displaced by ketoconazole, an imidazole-containing broad-spectrum cytochrome P450 inhibitor, with a consistent submicromolar potency (Higashi et al, 1987;Yang et al, 2002). Second, it was also fully inhibited by the three imidazole-containing compounds, ciproxifan, thioperamide, and clobenpropit, with submicromolar potencies similar to those found at adrenal P450 enzymes (LaBella et al, 1992;Yang et al, 2002) but two orders of magnitude lower than their affinities at rat H 3 Rs (Stark et al, 2001). Although H 3 R agonists contain the imidazole ring, which inhibits P450 isozymes through coordination with their heme moiety, they lack the lipophilic side chain present in antagonists.…”
Section: Discussionmentioning
confidence: 75%
“…Whatever the real value of K0.5, it is more than one order of magnitude lower than previously reported for other heme proteins. Indeed cytochrome P450 has an affinity for histamine of 16 #M (12). Similarly, the affinity reported for thromboxane synthase for imidazole and histamine were of 46 #M and >500 #M, respectively (based on inhibition of thromboxane B2 synthesis) (8).…”
mentioning
confidence: 97%
“…Potential interaction of imidazole H 3 R antagonists with cytochrome P450 enzymes is also of note since metyrapone, a cytochrome P450 inhibitor, markedly improves the specific H 3 R binding of radiolabeled thioperamide and clobenpropit (Alves-Rodrigues et al, 1996;Harper et al, 1999). In addition, thioperamide has been shown to bind cytochrome P450 enzymes and inhibit adrenal steroidogenesis (Labella et al, 1992). Interestingly, the imidazole moiety is found in other drug molecules that have been shown to inhibit this important metabolic pathway (Halpert et al, 1994).…”
mentioning
confidence: 99%